Tuberculosis in Saudi Arabia: Prevalence and antimicrobial resistance

Journal of Chemotherapy

Volumn 24, Issue 1, 2012, Pages 1-5

  Yezli, Saber ^a   Memish, Ziad A ^b  

^a Bioquell UK Ltd   (United Kingdom)

^b MINISTRY OF HEALTH   (Saudi Arabia)

Author keywords

Ethambutol; Isoniazid; Multidrug resistant; Mycobacterium tuberculosis; Rifampicin; Saudi Arabia

Indexed keywords

AMIKACIN; CAPREOMYCIN; ETHAMBUTOL; ISONIAZID; KANAMYCIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIAL TRANSMISSION; BACTERIUM ISOLATE; DRUG RESISTANT TUBERCULOSIS; EPIDEMIC; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; GEOGRAPHIC DISTRIBUTION; HEALTH CARE PERSONNEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; LATENT TUBERCULOSIS; LUNG TUBERCULOSIS; MORTALITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; REVIEW; SAUDI ARABIA; TUBERCULIN TEST; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; COMMUNICABLE DISEASES, EMERGING; DRUG RESISTANCE, MICROBIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; SAUDI ARABIA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84866245613     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1120009X12Z.0000000001     Document Type: Review

References (46)

1. Rook GA, Dheda K, Zumla A. Immune responses to tuberculosis in developing countries: implications for new vaccines. Nat Rev Immunol. 2005;5:661-7.
2. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol Rev. 2001;23:288-301.
3. Meya DB, McAdam KP. The TB pandemic: an old problem seeking new solutions. J Intern Med. 2007;261:309-29.
4. Lienhardt C, Fielding K, Sillah J, Tunkara A, Donkor S, Manneh K, et al. Risk factors for tuberculosis infection in subSaharan Africa: a contact study in The Gambia. Am J Respir Crit Care Med. 2003;168:448-55.
5. Schluger NW, Rom WN. The host immune response to tuberculosis. Am J Respir Crit Care Med. 1998;157:679-91.
6. Al-Jahdali H, Memish ZA, Menzies D. Tuberculosis in association with travel. Int J Antimicrob Agents. 2003;21: 125-30.
7. Alzeer AH. Respiratory tract infection during Hajj. Ann Thorac Med. 2009;4:50-3.
8. Alzeer A, Mashlah A, Fakim N, Al-Sugair N, Al-Hedaithy M, Al-Majed S, et al. Tuberculosis is the commonest cause of pneumonia requiring hospitalization during Hajj (pilgrimage to Makkah). J Infect. 1998;36:303-6.
9. Wilder-Smith A, Foo W, Earnest A, Paton NI. High risk of Mycobacterium tuberculosis infection during the Hajj pilgrim-age. Trop Med Int Health. 2005;10:336-9.
10. World Health Organization. Global tuberculosis control 2009: a short update to the 2009 report. Geneva, Switzerland (WHO/ HTM/TB/2009 426) 2010.
11. Ministry of Health. Health statistical year book 1428 H (2007). Riyadh, Saudi Arabia. 2008.
12. Al-Tawfiq JA, Al-Muraikhy AA, Abed MS. Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. Chest. 2005;128:3229-32.
13. Omair MA, Al-Ghamdi AA, Alrajhi AA. Incidence of tuberculosis in people living with the human immunodeficiency virus in Saudi Arabia. Int J Tuberc Lung Dis. 2010;14:600-3.
14. Al-Kassimi FA, Abdullah AK, Al-Hajjaj MS, al-Orainey IO, Bamgboye EA, Chowdhury MN. Nationwide community survey of tuberculosis epidemiology in Saudi Arabia. Tuber Lung Dis. 1993;74:254-60.
15. Khan MY, Kinsara AJ, Osoba AO, Wali S, Samman Y, Memish Z. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia. Int J Antimicrob Agents. 2001;17:415-8.
16. Hutchison DC, Drobniewski FA, Milburn HJ. Management of multiple drug-resistant tuberculosis. Respir Med. 2003;97:65-70.
17. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Virú FA, Shin SS, et al. Programmes and principles in treatment of multidrugresistant tuberculosis. Lancet. 2004;363:474-81.
18. World Health Organization. Case definition for extensively drug-resistant tuberculosis. Wkly Epidemiol Rec. 2006;81:408.
19. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet. 2006;368:1575-80.
20. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47:496-502.
21. World Health Organization. Multidrug and extensively drugresistant TB (M/XDR-TB): 2010 global report on surveillance and response. Geneva, Switzerland (WHO/HTM/TB/2010.3). 2010.
22. Abu-Amero KK. Status of antituberculosis drug resistance in Saudi Arabia 1979-98. East Mediterr Health J. 2002;8:664-70.
23. Alrajhi AA, Al-Barrak AM. Mycobacterium tuberculosis susceptibility in Saudi Arabia. Saudi Med J. 2002;23:1227-31.
24. Al-Hajoj SA. Tuberculosis in Saudi Arabia: can we change the way we deal with the disease? J Infect Public Health. 2010;3:17-24.
25. Ellis ME, al-Hajjar S, Bokhari H, Hussein Qadri SM. High proportion of multi-drug resistant Mycobacterium tuberculosis in Saudi Arabia. Scand J Infect Dis. 1996;28:591-5.
26. Kordy FN, Al-Thawadi S, Alrajhi AA. Drug resistance patterns of Mycobacterium tuberculosis in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis. 2004;8:1007-11.
27. al-Orainey IO, Saeed ES, el-Kassimi FA, al-Shareef N. Resistance to antituberculosis drugs in Riyadh, Saudi Arabia. Tubercle. 1989;70:207-10.
28. Al-Hajjaj MS, Al-Kassimi FA, Al-Mobeireek AF, Alzeer AH. Progressive rise of Mycobacterium tuberculosis resistance to rifampicin and streptomycin in Riyadh, Saudi Arabia. Respirology. 2001;6:317-22.
29. Zaman R. Tuberculosis in Saudi Arabia: initial and secondary drug resistance among indigenous and non-indigenous populations. Tubercle. 1991;72:51-5.
30. Kinsara AJ, Gilpin C, Soba AO. Review of tuberculosis at the King Khalid National Guard Hospital, Jeddah. Saudi Med J. 1997;19:212-4.
31. Jarallah JS, Elias AK, al Hajjaj MS, Bukhari MS, al Shareef AH, al-Shammari SA. High rate of rifampicin resistance of Mycobacterium tuberculosis in the Taif region of Saudi Arabia. Tuber Lung Dis. 1992;73:113-5.
32. Al-Rubaish AM, Madania AA, Al-Muhanna FA. Drug resistance pulmonary tuberculosis in the Eastern Province of Saudi Arabia. Saudi Med J. 2001;22:776-9.
33. Schiott CR, Engbaek HC, Vergmann B, Al-Motez M, Kassim I. Incidence of drug resistance amongst isolates of Mycobacterium tuberculosis recovered in the Gizan Area, Saudi Arabia. Saudi Med J. 1986;7:363-8.
34. Al-Hajjaj MS. The outcome of tuberculosis treatment after implementation of the national tuberculosis control program in Saudi Arabia. Ann Saudi Med. 2000;20:125-8.
35. Al Jahdali HH, Baharoon S, Abba AA, Memish ZA, Alrajhi AA, AlBarrak A, et al. Saudi guidelines for testing and treatment of latent tuberculosis infection. Ann Saudi Med. 2010;30:38-49.
36. Al-Hajoj SA, Zozio T, Al-Rabiah F, Mohammad V, Al-Nasser M, Sola C, et al. First insight into the population structure of Mycobacterium tuberculosis in Saudi Arabia. J Clin Microbiol. 2007;45:2467-73.
37. Al Hajoj S, Rastogi N. The emergence of Beijing genotype of Mycobacterium tuberculosis in the Kingdom of Saudi Arabia. Ann Thorac Med. 2010;5:149-52.
38. van Soolingen D, Kremer K. Findings and ongoing research in the molecular epidemiology of tuberculosis. Kekkaku. 2009;84:83-9.
39. Abbas MA, Alhamdan NA, Fiala LA, Elenezy AK, Alqahtani MS. Prevalence of latent TB among health care workers in four major tertiary care hospitals in Riyadh, Saudi Arabia. J Egypt Public Health Assoc. 2010;85:61-71.
40. Schablon A, Beckmann G, Harling M, Diel R, Nienhaus A. Prevalence of latent tuberculosis infection among health care workers in a hospital for pulmonary diseases. J Occup Med Toxicol. 2009;4:1.
41. Rafiza S, Rampal KG, Tahir A. Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia. BMC Infect Dis. 2011;11:19.
42. Torres CJ, Silva R, Sa R, Cardoso MJ, Nienhaus A. Results of five-year systematic screening for latent tuberculosis infection in healthcare workers in Portugal. J Occup Med Toxicol. 2010;5:22.
43. Caǧlayan V, Ak O, Dabak G, Damadoǧlu E, Ketenci B, Ozdemir M, et al. Comparison of tuberculin skin testing and QuantiFERON-TB Gold-In Tube test in health care workers. Tuberk Toraks. 2011;59:43-7.
44. Al-Hajoj SA, Alrabiah FA. Role of tuberculosis laboratories in Saudi Arabia. A call to implement standardized procedures. Saudi Med J. 2004;25:1545-8.
45. al-Orainey IO. Resistance to standard antituberculous drugs in Saudi Arabia. Saudi Med J. 1986;7:363-8.
46. Shank NJ, Khalifa I, Al-Kalai D. Tuberculosis in Saudi Arabia. Saudi Med J. 1983;4:151-6.